MYO18B promotes hepatocellular carcinoma progression by activating PI3K/AKT/mTOR signaling pathway
- PDF / 2,688,782 Bytes
- 9 Pages / 595.276 x 790.866 pts Page_size
- 65 Downloads / 179 Views
RESEARCH
Open Access
MYO18B promotes hepatocellular carcinoma progression by activating PI3K/AKT/mTOR signaling pathway Zhenyu Zhang1, Jinfeng Zhu2, Yansong Huang3, Weibing Li3 and Hongqiu Cheng3*
Abstract Background: MYO18B has been identified as a novel tumor suppressor gene in several cancers. However, its specific roles in the progression of hepatocellular carcinoma (HCC) has not been well defined. Methods: We firstly identified the expression and prognostic values of MYO18B in HCC using TCGA cohort and our clinical data. Then, MYO18B knockdown by RNA inference was implemented to investigate the effects of MYO18B on HCC cells. Quantitative RT-PCR and Western blot were used to determine gene and protein expression levels. CCK-8 and colony formation assays were performed to examine cell proliferation capacity. Wound healing and transwell assays were used to evaluate the migration and invasion of HepG2 cells. Results: MYO18B was overexpressed and correlated with poor prognosis in HCC. MYO18B expression was an independent risk factor for overall survival. Knockdown of MYO18B significantly inhibited the proliferation, migration and invasion of HepG2 cells. Meanwhile, MYO18B knockdown could effectively suppress the phosphorylation of PI3K, AKT, mTOR and P70S6K, suggesting that MYO18B might promote HCC progression by targeting PI3K/AKT/mTOR signaling pathway. Conclusions: MYO18B promoted tumor growth and migration via the activation of PI3K/AKT/mTOR signaling pathway. MYO18B might be a promising target for clinical intervention of HCC. Keywords: Hepatocellular carcinoma, MYO18B, PI3K/AKT/mTOR signaling pathway, Prognosis
Background Hepatocellular carcinoma (HCC) is the most common primary liver cancer, representing the fifth most common cancer and the third leading cause of cancer death worldwide [1]. It is well known that persistent infections by HBV or HCV are the primary inducers of chronic liver disease, thereby resulting in liver cirrhosis and HCC [2, 3]. Aflatoxin exposure and alcohol abuse are also important risk factors for developing HCC [2]. Surveillance by biannual ultrasonography is recommended for such patients [4, 5]. Current treatment options mainly include resection, liver transplantation and interventional radiology [5]. Although recent advances in therapies have achieved improved prognoses for * Correspondence: [email protected] 3 Department of Infectious Diseases, The Second Affiliated Hospital of Shantou University Medical College, NO. 69 Dongxia North Road, Shantou 515041, People’s Republic of China Full list of author information is available at the end of the article
patients with HCC, it is still involved in a poor survival rate due to late diagnosis [6]. Currently, patients with advanced HCC lack effective therapies, representing a unique clinical challenge. Given the current burden of HCC, identifying biomarkers associated with the progression and prognosis of HCC is a promising approach to make early diagnosis, predict prognosis and develop novel therapeutic strategies. Over the past dec
Data Loading...
